Matthew P. Blischak - 09 Jun 2023 Form 4/A - Amendment Insider Report for Finch Therapeutics Group, Inc. (FNCH)

Role
Chief Executive Officer
Signature
By: /s/ Matthew P. Blischak
Issuer symbol
FNCH
Transactions as of
09 Jun 2023
Net transactions value
$0
Form type
4/A - Amendment
Filing time
23 Jun 2023, 16:30:12 UTC
Date Of Original Report
09 Jun 2023
Previous filing
09 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FNCH Stock Option (right to buy) Award $0 +962,899 $0.000000 962,899 09 Jun 2023 Common Stock 962,899 $0.2710 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On June 9, 2023, the Reporting Person filed a Form 4, which, due to administrative error, inadvertently reported that the reported stock options were granted on June 8, 2023 with a strike price of $0.285, the closing price of the issuer's common stock on such date, and expiration date of June 7, 2033. In fact, as reported in this amendment, the reported stock options were granted on June 9, 2023 with a strike price of $0.271, the closing price of the issuer's common stock on such date, and expiration date of June 8, 2033.
F2 Twenty-five percent (25%) of the shares subject to this option shall vest on June 9, 2024, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such date.

Remarks:

The share prices and amounts reported in this Form 4 do not give effect to the issuer's 1-for-30 reverse stock split effected on June 9, 2023 subsequent to the stock option grant reported herein.